PARP1 and bladder transitional cell carcinoma: Because most studies with PARP inhibitors in BLCA have been performed using Olaparib, we first aimed to compare the potency of the latest generation PARP inhibitor Talazoparib to Olaparib in dose-response assays (Figure 2).